Moderna (MRNA) Stock Jumps 16% Following Positive Flu Vaccine Results and Wall Street Upgrades

Moderna (MRNA) stock rose 16% on Phase 3 flu vaccine data published in NEJM showing superiority, plus analyst upgrades from Evercore, Goldman, and Piper.

The post Moderna (MRNA) Stock Jumps 16% Following Positive Flu Vaccine Results and Wall Street Upgrades appeared first on Blockonomi.